These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 31514052

  • 1. Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.
    Sze JH, Raninga PV, Nakamura K, Casey M, Khanna KK, Berners-Price SJ, Di Trapani G, Tonissen KF.
    Redox Biol; 2020 Jan; 28():101310. PubMed ID: 31514052
    [Abstract] [Full Text] [Related]

  • 2. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF.
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Investigating the Thioredoxin and Glutathione Systems' Response in Lymphoma Cells after Treatment with [Au(d2pype)2]CL.
    Wang S, Lu Y, Woods K, Di Trapani G, Tonissen KF.
    Antioxidants (Basel); 2021 Jan 13; 10(1):. PubMed ID: 33451071
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
    Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF.
    Cell Cycle; 2016 Jan 13; 15(4):559-72. PubMed ID: 26743692
    [Abstract] [Full Text] [Related]

  • 8. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.
    Rackham O, Nichols SJ, Leedman PJ, Berners-Price SJ, Filipovska A.
    Biochem Pharmacol; 2007 Oct 01; 74(7):992-1002. PubMed ID: 17697672
    [Abstract] [Full Text] [Related]

  • 9. Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth.
    Johnson SS, Liu D, Ewald JT, Robles-Planells C, Pulliam C, Christensen KA, Bayanbold K, Wels BR, Solst SR, O'Dorisio MS, Menda Y, Spitz DR, Fath MA.
    Cancer Biol Ther; 2024 Dec 31; 25(1):2382524. PubMed ID: 39054566
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of Radiation Response in Breast Cancer Stem Cells by Inhibition of Thioredoxin- and Glutathione-Dependent Metabolism.
    Rodman SN, Spence JM, Ronnfeldt TJ, Zhu Y, Solst SR, O'Neill RA, Allen BG, Guan X, Spitz DR, Fath MA.
    Radiat Res; 2016 Oct 31; 186(4):385-395. PubMed ID: 27643875
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
    Liu JJ, Liu Q, Wei HL, Yi J, Zhao HS, Gao LP.
    Pharmazie; 2011 Jun 31; 66(6):440-4. PubMed ID: 21699084
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
    Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng QH, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B.
    Cancer Res; 2019 Jan 01; 79(1):125-132. PubMed ID: 30401714
    [Abstract] [Full Text] [Related]

  • 13. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
    Prast-Nielsen S, Cebula M, Pader I, Arnér ES.
    Free Radic Biol Med; 2010 Dec 01; 49(11):1765-78. PubMed ID: 20851179
    [Abstract] [Full Text] [Related]

  • 14. Gold(I) NHC Complexes: Antiproliferative Activity, Cellular Uptake, Inhibition of Mammalian and Bacterial Thioredoxin Reductases, and Gram-Positive Directed Antibacterial Effects.
    Schmidt C, Karge B, Misgeld R, Prokop A, Franke R, Brönstrup M, Ott I.
    Chemistry; 2017 Feb 03; 23(8):1869-1880. PubMed ID: 27865002
    [Abstract] [Full Text] [Related]

  • 15. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
    Schuh E, Pflüger C, Citta A, Folda A, Rigobello MP, Bindoli A, Casini A, Mohr F.
    J Med Chem; 2012 Jun 14; 55(11):5518-28. PubMed ID: 22621714
    [Abstract] [Full Text] [Related]

  • 16. Gold(i) and gold(iii) phosphine complexes: synthesis, anticancer activities towards 2D and 3D cancer models, and apoptosis inducing properties.
    Srinivasa Reddy T, Privér SH, Rao VV, Mirzadeh N, Bhargava SK.
    Dalton Trans; 2018 Nov 21; 47(43):15312-15323. PubMed ID: 30187047
    [Abstract] [Full Text] [Related]

  • 17. Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands.
    Vergara E, Casini A, Sorrentino F, Zava O, Cerrada E, Rigobello MP, Bindoli A, Laguna M, Dyson PJ.
    ChemMedChem; 2010 Jan 21; 5(1):96-102. PubMed ID: 19937669
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.
    Oncotarget; 2016 Nov 29; 7(48):78896-78909. PubMed ID: 27806331
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.